KR20140145575A - 폴리오바이러스 스트레인의 식별 - Google Patents
폴리오바이러스 스트레인의 식별 Download PDFInfo
- Publication number
- KR20140145575A KR20140145575A KR1020147019275A KR20147019275A KR20140145575A KR 20140145575 A KR20140145575 A KR 20140145575A KR 1020147019275 A KR1020147019275 A KR 1020147019275A KR 20147019275 A KR20147019275 A KR 20147019275A KR 20140145575 A KR20140145575 A KR 20140145575A
- Authority
- KR
- South Korea
- Prior art keywords
- sequence
- poliovirus
- seq
- oligonucleotide
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000991587 Enterovirus C Species 0.000 title claims abstract description 149
- 239000002773 nucleotide Substances 0.000 claims abstract description 125
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 125
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 123
- 238000000034 method Methods 0.000 claims abstract description 92
- 239000000523 sample Substances 0.000 claims abstract description 70
- 238000009396 hybridization Methods 0.000 claims abstract description 48
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims abstract description 36
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 30
- 230000003321 amplification Effects 0.000 claims abstract description 27
- 238000003556 assay Methods 0.000 claims abstract description 9
- 102000004190 Enzymes Human genes 0.000 claims abstract description 6
- 108090000790 Enzymes Proteins 0.000 claims abstract description 6
- 239000000872 buffer Substances 0.000 claims abstract description 4
- 241000274177 Juniperus sabina Species 0.000 claims description 94
- 230000002441 reversible effect Effects 0.000 claims description 63
- 150000007523 nucleic acids Chemical class 0.000 claims description 54
- 108020004707 nucleic acids Proteins 0.000 claims description 52
- 102000039446 nucleic acids Human genes 0.000 claims description 52
- 230000000295 complement effect Effects 0.000 claims description 51
- 108091093088 Amplicon Proteins 0.000 claims description 48
- OXSYGCRLQCGSAQ-UHFFFAOYSA-N CC1CCC2N(C1)CC3C4(O)CC5C(CCC6C(O)C(O)CCC56C)C4(O)CC(O)C3(O)C2(C)O Chemical compound CC1CCC2N(C1)CC3C4(O)CC5C(CCC6C(O)C(O)CCC56C)C4(O)CC(O)C3(O)C2(C)O OXSYGCRLQCGSAQ-UHFFFAOYSA-N 0.000 claims description 27
- 101100388690 Plasmodium falciparum (isolate K1 / Thailand) MEF-1 gene Proteins 0.000 claims description 19
- 239000002299 complementary DNA Substances 0.000 claims description 18
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 9
- 230000003612 virological effect Effects 0.000 claims description 7
- 229920005862 polyol Polymers 0.000 claims description 3
- 150000003077 polyols Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 20
- 229960005486 vaccine Drugs 0.000 abstract description 20
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract description 12
- 239000013615 primer Substances 0.000 description 195
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 239000002987 primer (paints) Substances 0.000 description 15
- 230000002238 attenuated effect Effects 0.000 description 12
- 241000709701 Human poliovirus 1 Species 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 208000000474 Poliomyelitis Diseases 0.000 description 8
- 230000009977 dual effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 102000012410 DNA Ligases Human genes 0.000 description 6
- 108010061982 DNA Ligases Proteins 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 230000008029 eradication Effects 0.000 description 4
- 238000013095 identification testing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000220259 Raphanus Species 0.000 description 3
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000709704 Human poliovirus 2 Species 0.000 description 2
- 241000709727 Human poliovirus 3 Species 0.000 description 2
- 102000004317 Lyases Human genes 0.000 description 2
- 108090000856 Lyases Proteins 0.000 description 2
- 241000158728 Meliaceae Species 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 241000589596 Thermus Species 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000007838 multiplex ligation-dependent probe amplification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102100029995 DNA ligase 1 Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229940124867 Poliovirus vaccine Drugs 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000205160 Pyrococcus Species 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000589499 Thermus thermophilus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 208000025223 poliovirus infection Diseases 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161570399P | 2011-12-14 | 2011-12-14 | |
| EP11193553 | 2011-12-14 | ||
| EP11193553.2 | 2011-12-14 | ||
| US61/570,399 | 2011-12-14 | ||
| PCT/NL2012/050887 WO2013095119A1 (en) | 2011-12-14 | 2012-12-14 | Identification of poliovirus strains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140145575A true KR20140145575A (ko) | 2014-12-23 |
Family
ID=48668876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147019275A Withdrawn KR20140145575A (ko) | 2011-12-14 | 2012-12-14 | 폴리오바이러스 스트레인의 식별 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20150031015A1 (enExample) |
| EP (1) | EP2791365A1 (enExample) |
| KR (1) | KR20140145575A (enExample) |
| CN (1) | CN104114719A (enExample) |
| IL (1) | IL232911A0 (enExample) |
| IN (1) | IN2014CN04405A (enExample) |
| MX (1) | MX2014007132A (enExample) |
| WO (1) | WO2013095119A1 (enExample) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5585477A (en) * | 1993-07-13 | 1996-12-17 | Us Health | Poliovirus specific primers |
| US20020150891A1 (en) * | 1994-09-19 | 2002-10-17 | Leroy E. Hood | Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region |
| WO1996015271A1 (en) | 1994-11-16 | 1996-05-23 | Abbott Laboratories | Multiplex ligations-dependent amplification |
| CA2255774C (en) | 1996-05-29 | 2008-03-18 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
| CA2268737A1 (en) * | 1997-08-07 | 1999-02-18 | Altwell Biotech. Inc. | Replication-competent recombinant sabin type 1 strain of poliovirus |
| AU3473399A (en) * | 1998-04-15 | 1999-11-01 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Poliovirus serotype-specific nucleic acids and methods for detecting specific serotypes of poliovirus |
| EP1130113A1 (en) | 2000-02-15 | 2001-09-05 | Johannes Petrus Schouten | Multiplex ligation dependent amplification assay |
| AU2001250572A1 (en) * | 2000-04-07 | 2001-10-23 | Epigenomics Ag | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
| JP2005224237A (ja) * | 2004-01-14 | 2005-08-25 | Toudai Tlo Ltd | 欠陥干渉粒子、ポリオウイルス欠損変異ＲＮＡ、ｃＤＮＡおよびプラスミド |
| US7476499B2 (en) * | 2006-06-16 | 2009-01-13 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of identifying anti-viral agents |
| CN102021248B (zh) * | 2009-09-09 | 2012-12-26 | 上海出入境检验检疫局动植物与食品检验检疫技术中心 | 食品中脊髓灰质炎病毒实时荧光rt-pcr检测方法和试剂盒 |
-
2012
- 2012-12-14 IN IN4405CHN2014 patent/IN2014CN04405A/en unknown
- 2012-12-14 EP EP12819147.5A patent/EP2791365A1/en not_active Withdrawn
- 2012-12-14 WO PCT/NL2012/050887 patent/WO2013095119A1/en not_active Ceased
- 2012-12-14 MX MX2014007132A patent/MX2014007132A/es not_active Application Discontinuation
- 2012-12-14 US US14/364,594 patent/US20150031015A1/en not_active Abandoned
- 2012-12-14 CN CN201280069697.7A patent/CN104114719A/zh active Pending
- 2012-12-14 KR KR1020147019275A patent/KR20140145575A/ko not_active Withdrawn
-
2014
- 2014-06-01 IL IL232911A patent/IL232911A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL232911A0 (en) | 2014-07-31 |
| IN2014CN04405A (enExample) | 2015-09-04 |
| EP2791365A1 (en) | 2014-10-22 |
| CN104114719A (zh) | 2014-10-22 |
| WO2013095119A1 (en) | 2013-06-27 |
| US20150031015A1 (en) | 2015-01-29 |
| MX2014007132A (es) | 2015-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2904120B1 (en) | Methods and reagents for detection, quantitation, and serotyping of dengue viruses | |
| JP6907202B2 (ja) | ウイルス由来の治療剤を解析する方法 | |
| JP7677950B2 (ja) | ｃｃｃＤＮＡから転写されたＨＢＶ ＲＮＡを含む、Ｂ型肝炎ウイルスＲＮＡの増幅および検出のための組成物および方法 | |
| CN114410836B (zh) | 一种集样本处理、核酸提取及多重恒温扩增一体化的检测人细小病毒b19的试剂盒和方法 | |
| EP4365312A2 (en) | A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype | |
| CN116171333A (zh) | 用于检测严重急性呼吸综合征冠状病毒2(sars-cov-2)、甲型流感和乙型流感的组合物和方法 | |
| JP7188645B2 (ja) | 非特異的な核酸増幅を抑制する方法 | |
| KR102648647B1 (ko) | 짧은 호모폴리머릭 반복서열의 개선된 검출법 | |
| Amexis et al. | Sequence diversity of Jeryl Lynn strain of mumps virus: quantitative mutant analysis for vaccine quality control | |
| WO2023279042A2 (en) | Compositions and methods for detection of severe acute respiratory syndrome coronavirus 2 variants | |
| KR20220164745A (ko) | 병원체 진단 시험 | |
| US11591660B2 (en) | Methods and reagents for detection of chikungunya virus or chikungunya virus and dengue virus | |
| TWI723675B (zh) | 用於檢測登革熱病毒的方法以及套組 | |
| JP2007514440A (ja) | Ｓａｒｓコロナウイルスを検出するための高感度かつ特異的な検査 | |
| JP5997764B2 (ja) | トルクテノウイルス診断 | |
| EP1466019A2 (en) | Detection of human papillomavirus e6 mrna | |
| CN101178350B (zh) | 检测狂犬病毒的试剂盒 | |
| JP6483336B2 (ja) | Ｈａｖ検出 | |
| US20150031015A1 (en) | Identification of poliovirus strains | |
| EP4375381B1 (en) | A method for determining the proportion of a live, attenuated dengue virus having a nucleotide sequence comprising at least one attenuation locus in a formulation | |
| CN113549709A (zh) | 利用巢式RPA技术检测SARS-CoV-2的引物对、探针、试剂盒及其应用 | |
| KR101567765B1 (ko) | 실시간 중합효소 연쇄반응을 통한 소파보바이러스의 정량 검출방법 | |
| US7427674B2 (en) | System and method for detecting West Nile Virus | |
| Kielich | Loop-mediated isothermal nucleic acid amplification coupled with CRISPR-Cas12b for rapid and sensitive detection of SARS-CoV-2 and Nipah virus | |
| Arjmand et al. | COVID-19 Diagnosis: A Comprehensive Review of Current Testing Platforms; Part A |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20140711 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |